Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/105892
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorCollege of Professional and Continuing Education-
dc.creatorYan, LS-
dc.creatorCui, S-
dc.creatorCheng, BCY-
dc.creatorYin, XB-
dc.creatorWang, YW-
dc.creatorQiu, XY-
dc.creatorNima, CR-
dc.creatorZhang, Y-
dc.creatorZhang, SF-
dc.date.accessioned2024-04-23T04:32:03Z-
dc.date.available2024-04-23T04:32:03Z-
dc.identifier.urihttp://hdl.handle.net/10397/105892-
dc.language.isoenen_US
dc.publisherDove Medical Press Ltd.en_US
dc.rights© 2023 Yan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).en_US
dc.rightsThe following publication Yan LS, Cui S, Cheng BCY, Yin XB, Wang YW, Qiu XY, Nima CR, Zhang Y, Zhang SF. Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways. Drug Des Devel Ther. 2023;17:297-312 is available at https://doi.org/10.2147/DDDT.S372981.en_US
dc.subjectAcute lung injuryen_US
dc.subjectLipopolysaccharideen_US
dc.subjectRAW264.7 macrophagesen_US
dc.subjectSichen formulaen_US
dc.subjectTLR4 signaling pathwaysen_US
dc.titleSichen formula ameliorates lipopolysaccharide-induced acute lung injury via blocking the TLR4 signaling pathwaysen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage297-
dc.identifier.epage312-
dc.identifier.volume17-
dc.identifier.doi10.2147/DDDT.S372981-
dcterms.abstractPurpose: Sichen (SC) formula is a classic prescription of Tibetan medicine. Due to its potential anti-inflammatory effect, the SC formula has been clinically used to treat respiratory diseases for many years in the Chinese Tibet region. The present study aimed to investigate the anti-inflammatory effect of SC and explore the underlying mechanisms.-
dcterms.abstractMethods: SC formula was characterized by HPLC analysis. The acute lung injury (ALI) mouse model was induced by direct intratracheal lipopolysaccharide (LPS) instillation, and bronchoalveolar lavage fluid (BALF) and lung tissues were collected. Meanwhile, RAW264.7 macrophages were stimulated by LPS. The contents of inflammatory mediators in the culture medium were determined by ELISA. Protein levels were determined by immunohistochemical staining or Western blotting. Nuclear localization of NF-κB, AP-1, and IRF3 was performed using immunofluorescence and Western blotting.-
dcterms.abstractResults: In the LPS-induced ALI mouse model, SC treatment suppressed the secretion of inflammatory mediators (TNF-α, IL-6, IL-1β, MCP-1, MIP-1α, and RANTES) in BALF. SC treatment hindered the recruitment of macrophages. SC treatment also inhibited the expression of CD68, p-p65, and TLR4 in the lung tissue. In the LPS-exposed RAW264.7 cells, the cell viability was not changed up to 400 μg/mL of SC. SC concentration-dependently suppressed the production of nitric oxide, prostaglandin E2, TNF-α, IL-6, MCP-1, MIP-1α, and RANTES in LPS-challenged RAW264.7 cells. The expression levels of iNOS, COX-2, p-p38, p-JNK, p-ERK, p-TBK1, p-IKKα/β, p-IκB, p-p65, p-c-Jun, and p-IRF3 were decreased after SC treatment. Moreover, the nuclear translocation of p65, c-Jun, and IRF3 was also blocked by SC treatment.-
dcterms.abstractConclusion: SC treatment inhibited the inflammatory responses in LPS-induced ALI mouse model/RAW264.7 macrophages. The underlying mechanism of this action may be closely associated with the suppression of TLR4 signaling pathways. These research findings provide further pharmacological justifications for the medicinal use of SC in the management of respiratory diseases.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationDrug design, development and therapy, 2023, v. 17, p. 297-312-
dcterms.isPartOfDrug design, development and therapy-
dcterms.issued2023-
dc.identifier.scopus2-s2.0-85147571102-
dc.identifier.pmid36756190-
dc.identifier.eissn1177-8881-
dc.description.validate202404 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextKey Science and Technology Research Projects of Tibet Autonomous Region of Chinaen_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Yan_Sichen_Formula_Ameliorates.pdf12.62 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

6
Citations as of Jun 30, 2024

SCOPUSTM   
Citations

4
Citations as of Jul 4, 2024

WEB OF SCIENCETM
Citations

3
Citations as of Jul 4, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.